News

Why AstraZeneca Stock Got Thumped on Thursday
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...
pharmaphorum15h
Summit climbs on rumour of $15bn AstraZeneca interest
Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...
Why Summit Therapeutics Stock Soared 8% Higher Today
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
4 questions to ask yourself before betting on AI in your business - and why
AI has the potential to democratize information and enhance productivity - but at Snowflake Summit 2025, business leaders ...
STAT1mon
ASCO 2025: Pfizer, AstraZeneca, Daiichi Sankyo, Summit
At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more. ... AstraZeneca’s plenary streak continues: ...
pharmaphorum6d
2nd Translational Digital Pathology & AI Summit
Don’t miss the return of the Translational Digital Pathology & AI Summit, uniting 60+ leading biopharma pioneers driving the ...